Preclinical models for evaluating hair and scalp aging solutions
QIMA Lifesciences offers preclinical models to test anti-aging compounds on hair and scalp. Using 3D dermal papilla fibroblasts, the models assess efficacy on gene and protein levels, focusing on hair growth and aging markers. Ideal for screening cosmetic and therapeutic agents.
Overview
QIMA Lifesciences presents a cutting-edge preclinical platform for evaluating the efficacy of anti-aging compounds targeting hair and scalp health. This innovative approach utilizes 3D dermal papilla (DP) fibroblasts to simulate in vitro models that assess cytotoxicity and anti-aging potential. By focusing on gene and protein level markers, such as DP inductivity and hair growth-related genes, this platform enables high-throughput screening of cosmetic and therapeutic agents aimed at preventing hair and scalp aging.
Technical specifications
- 3D-DP Fibroblasts Model: Provides a robust in vitro system for testing 20 compounds at varying concentrations to evaluate cytotoxicity and anti-aging effects.
- Gene and Protein Level Evaluation: Focuses on markers such as alkaline phosphatase, versican, IGF-1, and hair growth-related genes like DKK1 and Lef-1.
- Holistic Study Potential: Enables selection of top compounds for further testing on human hair follicle ex vivo models, assessing prevention of H2O2-induced aging and BrdU-induced senescence.
- Comprehensive Readouts: Includes analysis of morphology, qRT-PCR for inductivity, hair growth, inflammatory, senescence, and DNA damage response genes.
Technology readiness level
This preclinical platform is at Technology Readiness Level 3, indicating it is in the active research and development phase with experimental proof of concept established.
About QIMA Lifesciences
QIMA Life Sciences is a specialized Contract Research Organization (CRO) and CDMO providing end-to-end research and testing services for the pharmaceutical, biotech, and cosmetic industries. The organization operates through a network of specialized laboratories, including entities such as QIMA Bioalternatives, QIMA Newtone, QIMA Monasterium, QIMA Skinpharma, and Oxiproteomics. Their scientific capabilities encompass in vitro, ex vivo, and clinical evaluation, utilizing advanced analytical platforms to support drug discovery, efficacy substantiation, and safety testing from early development stages through to clinical trials. By integrating multidisciplinary expertise in cellular and molecular pharmacology, dermatology, and image processing, they deliver customized, science-driven strategies designed to accelerate development timelines and optimize research outcomes for global clients.
These services are critical for partners seeking to substantiate product claims, improve the success rates of drug candidates, or navigate complex regulatory environments. QIMA Life Sciences leverages state-of-the-art facilities—including over 10,000 square meters of laboratory space and clinical infrastructure equipped for Phase I to IV trials—to provide robust, regulatory-aligned data. With nearly 30 years of experience and a team of over 600 professionals, the organization supports clients in making data-backed R&D decisions. Their commitment to innovation is evidenced by extensive scientific output, including hundreds of published works, which helps clients in the beauty, healthcare, and veterinary sectors ensure their products meet rigorous quality and performance standards.
delivered to your inbox.